NCT01282970View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

July 31, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 135585

oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days

DRUG

Placebo to BI 135585

oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days

Trial Locations (1)

Unknown

1283.2.1 Boehringer Ingelheim Investigational Site, Neuss

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY